Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient

J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e7-e8. doi: 10.1111/jdv.14430. Epub 2017 Jul 20.

Authors

P Koelblinger^{1

2}, R Dummer², M Laimer¹, S Hecht³, J W Bauer¹, A Gaggl⁴, A Kugler¹

Affiliations

¹ Department of Dermatology, Paracelsus Medical University, 5020, Salzburg, Austria.
² Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
³ Department of Radiology, Paracelsus Medical University, 5020, Salzburg, Austria.
⁴ Department of Oral and Maxillofacial Surgery, Paracelsus Medical University, 5020, Salzburg, Austria.

PMID: 28646606
DOI: 10.1111/jdv.14430

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Anilides / adverse effects
Anilides / therapeutic use*
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Carcinoma, Basal Cell / drug therapy*
Everolimus
Humans
Immunosuppressive Agents
Kidney Transplantation*
Male
Neoplasm Recurrence, Local / drug therapy*
Nose Neoplasms / drug therapy*
Pyridines / adverse effects
Pyridines / therapeutic use*
Skin Neoplasms / drug therapy*

Substances

Anilides
Antineoplastic Agents
HhAntag691
Immunosuppressive Agents
Pyridines
Everolimus